Literature DB >> 30099569

Stability analysis of a steady state of a model describing Alzheimer's disease and interactions with prion proteins.

Mohammed Helal1, Angélique Igel-Egalon2, Abdelkader Lakmeche1, Pauline Mazzocco3, Angélique Perrillat-Mercerot4, Laurent Pujo-Menjouet5,6, Human Rezaei2, Léon M Tine7,8.   

Abstract

Alzheimer's disease (AD) is a neuro-degenerative disease affecting more than 46 million people worldwide in 2015. AD is in part caused by the accumulation of A[Formula: see text] peptides inside the brain. These can aggregate to form insoluble oligomers or fibrils. Oligomers have the capacity to interact with neurons via membrane receptors such as prion proteins ([Formula: see text]). This interaction leads [Formula: see text] to be misfolded in oligomeric prion proteins ([Formula: see text]), transmitting a death signal to neurons. In the present work, we aim to describe the dynamics of A[Formula: see text] assemblies and the accumulation of toxic oligomeric species in the brain, by bringing together the fibrillation pathway of A[Formula: see text] peptides in one hand, and in the other hand A[Formula: see text] oligomerization process and their interaction with cellular prions, which has been reported to be involved in a cell-death signal transduction. The model is based on Becker-Döring equations for the polymerization process, with delayed differential equations accounting for structural rearrangement of the different reactants. We analyse the well-posedness of the model and show existence, uniqueness and non-negativity of solutions. Moreover, we demonstrate that this model admits a non-trivial steady state, which is found to be globally stable thanks to a Lyapunov function. We finally present numerical simulations and discuss the impact of model parameters on the whole dynamics, which could constitute the main targets for pharmaceutical industry.

Entities:  

Keywords:  Alzheimer’s disease; Mathematical model analysis; Numerical simulations; Prions; Steady state

Mesh:

Substances:

Year:  2018        PMID: 30099569     DOI: 10.1007/s00285-018-1267-1

Source DB:  PubMed          Journal:  J Math Biol        ISSN: 0303-6812            Impact factor:   2.259


  30 in total

1.  Memory impairment in transgenic Alzheimer mice requires cellular prion protein.

Authors:  David A Gimbel; Haakon B Nygaard; Erin E Coffey; Erik C Gunther; Juha Laurén; Zachary A Gimbel; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

2.  Alzheimer's disease: a mathematical model for onset and progression.

Authors:  Michiel Bertsch; Bruno Franchi; Norina Marcello; Maria Carla Tesi; Andrea Tosin
Journal:  Math Med Biol       Date:  2017-06-01       Impact factor: 1.854

3.  Pathways of Amyloid-β Aggregation Depend on Oligomer Shape.

Authors:  Bogdan Barz; Qinghua Liao; Birgit Strodel
Journal:  J Am Chem Soc       Date:  2017-12-28       Impact factor: 15.419

4.  The prion protein as a receptor for amyloid-beta.

Authors:  Helmut W Kessels; Louis N Nguyen; Sadegh Nabavi; Roberto Malinow
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

Review 5.  The cholinergic hypothesis of Alzheimer's disease: a review of progress.

Authors:  P T Francis; A M Palmer; M Snape; G K Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

Review 6.  Regulation of APP cleavage by alpha-, beta- and gamma-secretases.

Authors:  J Nunan; D H Small
Journal:  FEBS Lett       Date:  2000-10-13       Impact factor: 4.124

7.  Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites.

Authors:  Darragh B Freir; Andrew J Nicoll; Igor Klyubin; Silvia Panico; Jessica M Mc Donald; Emmanuel Risse; Emmanuel A Asante; Mark A Farrow; Richard B Sessions; Helen R Saibil; Anthony R Clarke; Michael J Rowan; Dominic M Walsh; John Collinge
Journal:  Nat Commun       Date:  2011-06-07       Impact factor: 14.919

8.  A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma.

Authors:  David L Craft; Lawrence M Wein; Dennis J Selkoe
Journal:  Bull Math Biol       Date:  2002-09       Impact factor: 1.758

9.  Modeling amyloid-beta as homogeneous dodecamers and in complex with cellular prion protein.

Authors:  Steven L Gallion
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

10.  Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.

Authors:  Juha Laurén; David A Gimbel; Haakon B Nygaard; John W Gilbert; Stephen M Strittmatter
Journal:  Nature       Date:  2009-02-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.